Vir Biotechnology Inc. Common Stock (VIR)

FairStock Score: 63/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I am wary when a clinical-stage biotech sells for $1.8B while earning little. Vir Biotechnology discovers and develops therapies for serious infectious diseases. Its filed results show losses in fiscal year 2023 (period ended 2023-12-31): revenue was $86.2M and net loss was $615.1M; fiscal year 2024 (period ended 2024-12-31): revenue was $74.2M and net loss was $522.0M; and fiscal year 2025 (period ended 2025-12-31): revenue was $68.6M and net loss was $438.0M. The latest report breaks the pattern: in fiscal Q2 2026 (quarter ended 2026-06-30), revenue was $238.9M and net income was $80.1M, with diluted EPS of $0.47. But fiscal Q1 2026 (quarter ended 2026-03-31) had negative revenue of $29,000 and a net loss of $125.7M. One profitable quarter is not a moat. The company's edge rests on its pipeline and intellectual property; clinical and regulatory success must prove it.

In plain English: Vir Biotechnology is a small healthcare company that works on treatments for serious infectious diseases. It has mostly lost money in recent years, though it reported a profit in the quarter ended June 30, 2026. At $10.61 on October 13, 2026, the shares are near the high end of their 52-week range and do not look clearly cheap against that weak history.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer